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ABSTRACT
THE ACTIVATION OF DOPAMINERGIC NEURONAL GROUPS
By
Remington J Rice
This study corroborates with evidence that increased activity in dopamine
pathways can cause hyperactive locomotion and other behaviors related to psychosis.
However, the involvement of these specific cell types in schizophrenia is not fully
understood. The psychostimulant amphetamine is one of the numerous compounds that
can alter dopamine concentrations all over the brain, leading to psychotic effects in
healthy humans. Administration of amphetamine to experimental animals has been used
to create models of schizophrenia; producing a unique array of behavioral effects, such as
hyper-locomotion and a collection of behaviors referred to as stereotypy. In contrast,
certain antipsychotic drugs that act directly upon dopaminergic neurons have been shown
to alleviate schizophrenic symptoms. Three weeks after the infusion of an adenoassociated viral vector into transgenic TH: Cre Sprague Dawley rats, a light sensitive
channel, will be expressed on dopaminergic neurons. Depolarization of the neuron
rapidly occurs after pulses of 465 nm wavelengths of light, blue light, are sent through a
fiber optic cable to the injection site. These dopaminergic cells exist in relatively high
concentrations throughout multiple brain regions. Optogenetic tools have been used to
selectively activate dopaminergic neurons in the ventral tegmental area (ventral tegmental
area) during behavioral assessment sessions. These findings validate past ideals about the
nature of dopaminergic pathways in the brain and their relation to mental illness.
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Schizophrenia

Schizophrenia is a mental disorder that encompasses a wide range of behavioral
patterns that can result in a severely reduced ability to function in everyday life. Since its
first description in the mid to late 1800s, the numerous life-altering symptoms have been
cataloged. However, the causes of these symptoms are incompletely understood.
Advancements in research techniques and pharmaceutical compounds have enhanced
humanity’s understanding of how the mental disorder affects the brain. The continuing
toil from scientists around the world will continue to decrease the suffering in patients
diagnosed with schizophrenia (Frith, 1987; Friston, 1992; Knapp, 2004; Shenton,
2001).
The term itself is a product from the Greek roots skhizein “to split” and phrën
“mind” (Kuhn & Cahn, 2004). Eugen Bleuler first used the term during a lecture in
Berlin on April 24th, 1908. In 1911, Bleular expanded on schizophrenia in his seminal
study Dementia Praecox, oder Gruppe der Schizophrenien (Dementia Praecox, or the
Group of Schizophrenias). It would be another 40 years until it was translated into
English. During this time, the ideas tested by Emil Kraepelin and Kurt Schneider also
added into the modern sense of the word (Andreasen, 1989). All three of these
researchers heavily influenced the definition of schizophrenia described by the American
Psychiatric Association in the Diagnostic and Statistical Manual (DSM-III).
The latest edition of the manual (DSM-V), carries over six different criteria (A-F)
from previous editions, to assist in the evaluation of patients. Typically, a diagnosis is
given when two symptoms from criteria A and at least one other are present for a
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significant amount of time (Tandon et al., 2013). Characteristic symptoms of
schizophrenia (Criterion A), are divided into positive and negative symptoms. Positive
symptoms are feelings or behaviors that are not usually present. The list of positive
symptoms includes delusions, hallucinations, disorganized speech, grossly disorganized,
and catatonic behavior. Negative symptoms are a lack of feelings or behaviors. Examples
of this include affective flattening, anhedonia, and alogia (American Psychiatric
Association, 2013). The DSM V continues and describes criterion B as social/
occupational dysfunctional. A duration of symptoms with no change for 6 months defines
criterion C. The remaining criteria are meant to exclude other explanations for the
symptoms. Criteria D-F attempt to ensure that the patient is not suffering from a mood
disorder, substance abuse, and/or autism spectrum disorder.
Schizophrenia occurs in about 7 people per 1000 (Saha, Chant, Welham, &
McGrath, 2005). A 2004 cost-of-illness study analyzed 62 peer-reviewed articles in an
attempt to calculate the societal burden of schizophrenia. The researchers summed up
direct, indirect, and intangible costs. Direct costs include payments made for various
therapies and treatments. When a disorder causes an individual to not be able to work in
society, it is categorized as an indirect cost; in other words, a resource is lost. The
intangible costs are described as pain or depression. Knapp (2004) collected past
estimates of cost and demonstrated that in the year 1990, this mental disorder put a $65
billion burden on the United States economy.
The societal costs of schizophrenia are severe, in part due to reduced life
expectancy for patients. The life expectancy for men with schizophrenia is below the
national average by 14.6 years (Chang et al., 2011). Chang et al. (2011) explained that the
impact of this serious mental illness on life expectancy is significant and commonly
2

higher than the corresponding impact of well-recognized adverse exposures such as
smoking, diabetes and obesity. Strategies to isolate and prevent causes of premature death
are urgently necessary.
In addition to a higher rate of suicide, 15% of patients also suffer from Type II
diabetes (Dixon et al., 2000). Dixon et al. (2000) demonstrated that this is significantly
higher than the national average and the patients’ health suffered in other areas; such as
decreased life satisfaction and an overall diminished quality of life. However, these
authors commented that 87% of the patients in the study were prescribed antipsychotic
compounds. This made determining if the poor health observed was due to the mental
illness or medication, the latter has been shown to have a host of adverse effects
(described below).
The causes of schizophrenia are unknown. Research has produced evidence that
environmental variables, brain structure, and genetic components factor into the complex
issue. Environmental factors such as drug use and prenatal stressors have all been
correlated with a portion of schizophrenic patients (Picchioni & Murray, 2007). In
addition to that premise, magnetic resonance imaging (MRI) studies have shown less
grey matter volume in the frontal cortex and temporal lobes (Hirayasu et al., 1998). There
is a 1% prevalence in the general population and near 50% for monozygotic twins or
having two biological parents with schizophrenia
(DiLalla & Gottesman, 1991). Finally, the increased odds of diagnosis between relatives
that have never met, shows that there is a strong heritability factor in the mental illness
(Kendler & Diehl, 1993). Many of the numerous potential causes have also been
connected with specific neurotransmission abnormalities. One of the theories put forth to
describe the causal mechanisms of schizophrenia is the dopamine hypothesis.
3

The Dopamine Hypothesis of Schizophrenia
In regard to proposals put forth to explain what dysfunctional mechanisms are
causing schizophrenia, the dopamine hypothesis has been one of the most prevailing. The
earliest versions of this hypothesis proposed that dopamine producing neurons in the
brain were hyperactive, leading to increased extracellular levels of dopamine (Meltzer &
Stahl, 1976, Haracz, 1982). The dopamine hypothesis was put forth after the discovery of
antipsychotic drugs and the observations that they could relieve some psychotic
symptoms (Delay, Deniker, & Harl, 1952). It was found that some of these drugs
accelerated the breakdown of dopamine in the brain (Carlsson & Lindqvist, 1963). In
addition to that, other compounds, namely reserpine, was also effective in treating
psychosis and it was discovered that it blocks the storage of monoamine vesicles and
essentially depletes dopamine in neurons (Carlsson, Lindqvist, & Magnusson, 1957). The
dopamine enhancing drug levodopa, which is used to treat Parkinson’s disease
symptoms, can also cause psychotic side effects similar to schizophrenia (Seaman,
1998).
Illicit substances such as amphetamine and cocaine increase dopamine release and
prevent recycling of the neurotransmitter in the synapse; this action has been shown to
induce psychotic symptoms (Lieberman, Kane, & Alvir, 1987). Lieberman discovered
that “amphetamine psychosis” is, in part due to an increase of synaptic monoamine
levels. With this evidence, the first version of the dopamine hypothesis put forth the idea
that increased dopamine levels would cause schizophrenia-like positive symptoms.
Later in the 20th century, a modified dopamine hypothesis of schizophrenia was
introduced (Davis, 1991). By this time, imaging data had narrowed down the effects into
4

specific regions. Evidence that the overactive neurons may be a mechanism of the
disorder, comes from positron emission tomography data (Friston, Liddle, Frith, Hirsch,
& Frackowiak, 1992). In 30 schizophrenic patients, a significant portion of the patients
had increased regional cerebral blood flow in left medial temporal region, mesencephalic,
thalamic and left striatal structures; with the highest concentration in the left
parahippocampal region. Similar MRI studies have confirmed the intense neuron activity
(Shenton, Dickey, Frumin, & McCarley, 2001).
Neuroimaging studies also support the dopamine hypothesis for schizophrenia.
Lim et al. (2012) confirmed dopamine type 2 (D2) receptor antagonists produce reduced
activity in some of the aforementioned areas. Eight male volunteers were given oral doses
of haloperidol once daily for seven days. Comparisons of PET scans before and after
treatment indicated more D2 receptor blockage with treatment. This knowledge has been
helpful in administrating “optimal” dosages to patients.

5

Dopaminergic Pathways of the Brain
Dopamine is released in the brain by neurons in the central nervous system and
functions as a neurotransmitter. Dopamine is a monoamine neurotransmitter, meaning
that it contains a single “amine” molecule. Amines are comprised of a basic nitrogen
atom with a pair of non-binding valence electrons. Dopamine is an amine derived from
the decarboxylation of L-DOPA. A widespread diversity of physiological function is
mediated by the D1, D2, D3, D4, and D5 G-protein couple receptors (Beaulieu et al., 2015).
Beaulieu’s (2015) review of dopamine receptor literature shows that dopamine receptor
actions extend past the action of cAMP signaling and influences numerous other cellular
responses, such as receptor desensitization.
Dopamine has been strongly implicated in the numerous physiological functions,
including the control of body temperature (Chaperon et al., 2003). Chaperon (2003)
demonstrated that a selective D1 antagonist SCH 23390 and selective D2 antagonist L741,626 would elicit hypothermia in experimental rats. Other research conducted with D3
knock-out rats demonstrated the same hypothermia as well as decreased locomotion
(Boulay, 1999). Other physiological functions will be described below, in conjunction
with the individual dopaminergic pathways responsible.
There are four major dopamine pathways in the human brain. The mesolimbic,
mesocortical, nigrostriatal, and tuberoinfundibular pathways.
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Figure 1. The ventral tegmental area has dopaminergic projections to the frontal
cortex (prefrontal cortex and other frontal lobe regions), the nucleus accumbens, the
striatum, and the tuberoinfundibular pathway extends through the hypothalamus to the
pituitary gland.
Current electrophysiological techniques have been challenged in discerning which
ventral tegmental area dopamine neurons project to the nucleus accumbens (and
elsewhere in the limbic system) or the prefrontal cortex (PFC). However, dual-probe
micro dialysis has been more enlightening about the nature of these neurons (Westerink,
Kwint, & deVries, 1996. German & Manaye, 1993). Researchers discovered that less
than 10% of the A10 (the identification of the ventral tegmental area in rats) dopamine
neurons project to the PFC. Florescent staining has confirmed this hypothesis as well.
Multiple fluorescent staining procedures have demonstrated that the projections to the
7

nucleus accumbens could account for up to 80% of dopaminergic neurons (Swanson,
1982). However, a wide diversity of neurons exists along with dopaminergic neurons.
Both glutamatergic neurons (Yamaguchi et al., 2007) and GABAergic neurons (Carr &
Sesack, 2000) exist and communicate with dopaminergic projections.
As noted earlier, the mesolimbic pathway has been shown to produce the
“positive” symptoms of schizophrenia (Gray et al., 1995). Gray (1995) demonstrated that
excess dopamine from the mesolimbic pathway contributes to difficulties in processing
incoming stimuli. The researcher reviewed studies that disrupted this pathway in animal
models with either surgical damage or systemic drug delivery and tested them with a
behavioral paradigm called latent inhibition. “Negative” symptoms such as reduced
emotional responsiveness (affective blunting) or social withdrawal has been connected to
diminished mesocortical pathway activity (Meltzer & Stahl, 1976; Gold et al., 2013).
Antipsychotic drug effects in the nigrostriatal pathway have been implicated in being
responsible for a type of drug-induced movement dysfunctions known as extrapyramidal
symptoms (Pierre, 2012). Finally, the tuberoinfundibular pathway is a group of dopamine
neurons that regulate the secretion of prolactin from the anterior pituitary gland
(described further below).
The “meso” prefix means “middle” in Greek, and refers to the midbrain or
“middle brain.” The mesolimbic and mesocortical pathways both stem from midbrain
regions, specifically the ventral tegmental area. This brain region overlaps in both
pathways, but there are distinct differences between the two. The differences can be
simply ascertained from looking at where the ventral tegmental area projects too. The
mesolimbic pathway consists of mid brain regions connected to the limbic system and the
mesocortical consists of midbrain regions communicating with the cerebral cortex.
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The largest group of dopaminergic neurons in the mesolimbic pathway stems
from the ventral tegmental area through the medial forebrain bundle to the nucleus
accumbens (German & Manaye, 1993). The ventral tegmental area also communicates
with the basal lateral amygdala in this pathway. The nucleus accumbens plays a major
role in pleasure, reward, motivation, and reinforcement learning (Wenzel, Rauscher,
Cheer, & Oleson, 2015). Wenzel (2015) found that dopamine signaling from the ventral
tegmental area influences motivated behavior and response to environmental stimuli. The
group of researchers used fast-scan cyclic voltammetry to show real-time increases in
nucleus accumbens dopamine concentrations when animals were presented with
predictors of aversion and its avoidance. This evidence clearly shows that dopamine
activity in the nucleus accumbens plays a role in moderating positive and negative stimuli
during adaptive behaviors. He continues and states that the nucleus accumbens is
composed of medium spiny neurons. Along with the dopaminergic neuronal projections
from the ventral tegmental area, the nucleus accumbens receives input from
glutamatergic neurons in the amygdala, hippocampus, and medial prefrontal cortex.
The mesocortical pathway connects the ventral tegmental area to the prefrontal
cortex. The prefrontal cortex carries out executive functions such as regulating voluntary
movement and planning for actions and is essential for working memory. These functions
have been strongly linked to the prefrontal cortex by analyzing deficits during various
behavioral paradigms such as the radial-arm maze, water maze, and attention tasks after
experimental animals received lesions or injections of excitotoxin (Romanides, et al.,
1999; Sakurai & Sugimoto, 1985; Viggiano, et al., 2002).
Recent fMRI experiments with healthy humans have shown neuronal activity to
increase in the PFC during periods of manic like behaviors (Passamonti et al., 2015).
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These behaviors have been linked to disorders associated with dopamine dysfunction
(Post, Jimerson, Bunney, & Goodwin, 1980). fMRI data in human beings collected by
Passamonti et al. (2015) has validated that this critical component of the prefrontal
cortex, is responsible for certain behaviors attributed with dopamine function. However,
fMRI results lack the specificity to determine exactly what cell types were active in those
areas.
Specific gene mutations that produce abnormal protein function in the
mesocoritcal pathway has been implicated in schizophrenia. A recent study has shown
that abnormal gene activity in the frontal lobe, specifically a functional polymorphism of
the Val and Catechol-O-methyltransferase (COMT) gene, can slightly increase risk for
schizophrenia (Egan et al., 2001). COMT is an enzyme that breaks down dopamine. The
researchers state that high activity of the COMT and Val alleles can compromise the
postsynaptic impact of dopamine response in the frontal cortex.
Furthermore, evidence is now demonstrating how both the mesolimbic and
mesocortical pathways communicate with each other (Laviolette, 2007). The image
below details how dysfunction in the pathways can give rise to symptoms of
schizophrenia. Laviolette (2007) makes it apparent that dysfunction of dopamine from the
ventral tegmental area plays a role with functions necessary for every day behaviors, such
as the encoding of emotional, motivational, and sensory inputs.
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Figure 2. When dopamine production in the ventral tegmental area is
dysregulated, this can have varying effects in multiple brain regions that are held
responsible for schizophrenic symptoms. The large arrows represent forward
dopaminergic projections that exist in the mesolimbic and neocortical pathways. The
small arrows represent feedback loops that exist in both pathways. This image
demonstrates that each pathway is intimately involved with each other. See the main text
for descriptions of specific regions and paths involved with individual pathway.
The nigrostriatal pathway is mostly involved in the production of movement and
loss of these dopamine neurons is one of the foremost pathological features of
Parkinson’s disease (Diaz, 1996). As noted earlier, antipsychotic compounds have been
shown to induce extrapyramidal side effects (EPS) in patients with schizophrenia. EPS
are drug induced movement disorders that include tardive dyskinesia, rigidity, and
restlessness. These symptoms are typically caused by antipsychotic drugs that antagonize
dopamine D2 receptors (Pierre, 2005). This notion will be explored further in latter
portions of this document.
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The last major dopamine pathway, the tuberoinfundibular pathway, is important
for the regulation of the release of prolactin. Prolactin is a luteotropic hormone that
enables mammals to produce milk and is involved in a large number of other hormonal
processes. The entire dissection of this endocrinology topic is outside the scope of this
document. However, it is important to note that the tuberoinfundibular pathway may not
be linked to the symptoms of schizophrenia, but antipsychotic drugs definitely exert
effects here (Clemens, Smalstig, & Sawyer, 1974). Clemens (1974) produced evidence
that prolactin concentrations increased after the administration of dopamine antagonizing
antipsychotic drugs. This excess of prolactin levels can cause hyperprolactinemia, which
can include infertility, loss of libido, erectile dysfunction, hypoestrogenism, and other life
altering symptoms (Melmed et al., 2011).
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Pharmacotherapy for Schizophrenia
Beginning in the 1950s, the scientific community has been gaining substantial
amounts of knowledge about which neurotransmitters are associated in schizophrenia. In
part, due to the development of selective drugs that allowed researchers to infer which
neurotransmitters are involved in schizophrenia. The development of compounds used to
treat Parkinson’s disease and the development of classical antipsychotic drugs advanced
our understanding which neurotransmitters are involved with schizophrenic symptoms.
Dopamine replacement therapy has helped patients with Parkinson’s disease gain some of
their motor function loss (Hornykiewicz et al., 1973). This therapy includes
administration of a precursor to dopamine, L-DOPA, and it effectively increases
dopamine concentrations. In contrast, some of the first antipsychotic drugs developed
have induced deficits in motor function similar to the motor symptoms of Parkinson’s
disease, which again is referred to as extra pyramidal symptoms. The first drugs that
caused this motor dysfunction, primarily chlorpromazine and haloperidol, are now
classified as “typical,” “classical,” or “first-generation” antipsychotic drugs; referred to as
typical antipsychotics for this document. Along with these side effects, these drugs
alleviate the positive symptoms of schizophrenia by blocking dopamine receptors
(Seaman, 1975) (Crow, 1980). As mentioned before, the decrease of dopamine and
decrease of psychotic symptoms caused by antipsychotic drugs, led to the concept that an
increase of dopamine activity caused psychosis. This was essential to the foundation of
the dopamine hypothesis of schizophrenia.
Since the development of the first antipsychotic drugs, new compounds have been
manufactured that produce a lower risk of extra pyramidal symptoms at therapeutically13

effective doses (Pierre, 2012). These are known as second generation antipsychotics, also
referred to as “atypical” or “novel” antipsychotic drugs. Atypical antipsychotics can still
produce other severe side effects as well including tardive dyskinesia (involuntary
repetitive body movements) and neuroleptic malignant syndrome (muscle rigidity, fever,
and cognitive deficits).
The World Health Organization (WHO) recommends the administration of
atypical antipsychotics as first line treatments for patients with schizophrenia. The effects
and reduction of symptoms may take as long as 6-8 weeks (Emsley et al., 2006). There
are several health organizations that offer a schematic and information to provide the
optimal drug administration in varying conditions (Taylor, Paton, & Kapur, 2015).
It is important to note at this time that most, if not all, antipsychotic drugs exert
effects on several different types of receptors and neurons all over the brain. However,
every antipsychotic drug does bind to D2 receptors, with the exception of one that is
claimed to be a partial agonist (aripiprazole). All other typical antipsychotic drugs are D2
antagonists and the typical antipsychotic drug haloperidol, like many others. also has a
binding affinity for noradrenergic and serotonin receptors (Schotte, Janssen, Megens, &
Leysen, 1993). Schotte (1993) put forth that the antagonism of the serotonin receptor 5HT2A could contribute to haloperidol’s reduction of hallucinations, delusions, and other
positive symptoms of schizophrenia. However, most atypical antipsychotic drugs have
greater affinity the antagonism of 5-HT2A receptors than D2 receptors (Meltzer, 1989;
Schotte et al., 1996). These series of experiments have made it clear that dopamine
receptors are important, but are not the only component involved with schizophrenia.
Diminished levels of glutamate release in the same areas that dopamine pathways
communicate with may also cause symptoms of schizophrenia (Paz, Tardito, Atzori, &
14

Tseng, 2008). Elevated concentrations of dopamine, has been shown to worsen positive
symptoms of schizophrenia (Laruelle et al., 1996). Laruelle (1996) administered
amphetamine to drug-free patients with schizophrenia and collected computerized
tomography data that detailed striatal dopamine release. Their data indicates that
schizophrenic patients had more D2 occupancy after amphetamine administration, when
compared to healthy individuals. This would imply that the patient’s neurons were
hypersensitive to dopamine. The dopamine hypothesis and other evidence provides a
better understanding of the mental illness. However, there is still important questions to
be answered within each individual hypothesis.
Animal models of schizophrenia have been vital in gaining knowledge to help
patients. It has been demonstrated that the dopamine antagonist raclopride, when coadministered with other antipsychotic drugs, can increase the dopamine concentrations in
the medial prefrontal cortex (Westerink et al., 2001, Farde et al., 1992). This synergism
of drugs is meant to reduce psychotic symptoms. Farde (1992) used D2 radioligands and
positron emission tomography (PET) to determine that raclopride quickly occupies D2
receptors in the basal ganglia. The basal ganglia is mainly comprised of dopaminergic
neurons that synapse onto gamma–Aminobutyric acid (GABA) producing neurons
(Tritsch, Ding, & Sabatini, 2012).
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Optogenetics
Francis Crick articulated in 1979 that in order to better understand the brain,
scientists would need to be able to control specific types of cells or individual neurons
(Crick, 1979). He stated that if this were possible, one could activate a single neuron and
watch the cascade of other neurons being activated. Or, alternatively, inhibit a neuron and
see what other cells around it followed. Crick continues and believed that this would
someday be possible. His knowledge of the visual system, a system of the brain that
responds to light, may have led to his thoughts that we could control specific types of
neurons in any part of the brain.
It is now possible to control specific cell types with high temporal and spatial
precision in the central nervous system (CNS) of mammals. In the past, electrical
stimulation has been able to target areas of the brain with temporal precision, but was not
cell specific; electric current will stimulate every type of cell in the area of effect (You,
1998). Drug research in the past has been able to target specific types of cells, but lacks
the ability to target specific areas. An example of a drug exhibiting these characteristics is
haloperidol. Haloperidol blocks dopamine transmission on D2 receptors located on many
different types of neurons throughout the brain (Seeman, 2002). The modern procedure
described in the coming pages, optogenetics, attempts to overcomes both of these
obstacles.
The development of optogenetics was cultivated from several different fields of
science. The microbial opsins involved in optogenetics are similar to the photoreceptor
cells produced in the human eye. Photoreceptor cells contain a pigment called retinal,
which transforms electromagnetic radiation (light) into electrical signals that are sent
16

further into the brain for processing. A photon of light is captured and causes
isomerization of retinal; an alteration in the molecular structure initiating the surge of
information. Using the technology of optogenetics, it is possible to induce expression of
similar photoreceptors onto targeted neurons in the brain, creating neurons that are
sensitive to light (Deisseroth, 2011).
However, humans are not the only species to have evolved machinery to sense
electromagnetic energy in their setting. For example, channelrhodopsin-2 (ChR2) is a
light-gated ion channel present in green algae Chlamydomonas reinhardtii (Nagel, 2003).
Unicellular green alga uses these photoreceptors to orient themselves in response to
sunlight. The photoreceptors belong to a family of rhodopsins that function as a channel
by absorbing a photon of light to create permeability for monovalent and divalent cations.
Researchers discovered the ChR channel in 1971 (Foster, 1980). Not until three and a
half decades later was the potential of this biological machine brought to light.
In 2005, Karl Deisseroth and Ed Boyden discovered a way to make mammalian
hippocampal cells sensitive to light through implantation of ChR2 (Boyden, 2011).
Shining blue light (473 nm wavelength photons) on these cells in vitro would cause them
to send nerve impulses 1-2 milliseconds later. Once the light was turned off, the cells
returned to normalcy. In their resting state, an electrical potential exists between the
interior of the cell and outside of the cell. When ChR2 was activated, its channel would
open and cause an influx of positive ions, acting to increase the internal cellular charge
and cause cellular depolarization. This process of neurons changing their electrical charge
and sending action potentials is a similar to the normal electrical communication that
occurs all over the brain during every emotion, action, and sensory input we perceive.
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In order to produce ChR2 in a mammalian brain, the genetic codes for the light
sensitive protein must be injected into each neuron with the help of a vector. The primary
vectors used in optogenetics, the adeno-associated viruses (AAVs), were discovered in
the 1960s. AAVs are infectious and non-pathogenic and have been used in various other
gene therapy techniques.
Another vital piece of the optogenetics puzzle is the light source. ChR2 is
activated about 1 mW of blue light, ~470 nm wavelengths (Lin, 2011). Diode-pumped
solid-state lasers have been the prevalent equipment to activate ChR2. Lasers can output
thousands of mWs into rotary components, brain matter, and long fiber optic cables. This
is important because each junction of the light path, such as the rotary component, can
cause a 50% loss of power. New light-emitting diode (LED) technology has been used
successfully. Several images in Appendix A show one LED arrangement. The advent of
LED fiber coupled equipment, with higher numerical aperture fiber, has made it possible
to use LEDs that are significantly less expensive than a laser setup.
Through lasers, genetic engineering, and the technology to use viral vectors, it is
now possible to produce and control these channels in mammalian brains. Optogenetics
creates neurons that can be excited or inhibited instantly (50-250 fS) and with great
precision (Nagel et al., 2003). Since the discovery of ChR2, several other channels have
been discovered. In general, Channelrhodopsins are excitatory, halorhodopsins silence
neurons by hyperpolarizing them, and archearhodposin works on similar principles as
halorhodopsin, but with higher affinity for mammalian neurons (Xue 2012).
The tools for optogenetic studies keep being refined and new tools are found constantly.
The ChR2 protein has also had some genetic mutations happen that scientists have
isolated for different variations. Zhao (2010) made use of the mutation ChR2(H134R).
18

This mutation allows the channel to stay open longer and is more sensitive to lower mWs
of light. This could benefit behavioral studies, where the effect of neural activation is
effective, making it easier to distinguish. These light gated ion channels also have an
EYFP florescent protein attached; this allows confirmation of the existence of these
channels.
Optogenetic tools are often used in conjunction with other genomic technologies,
a common pairing includes Cre/Lox recombination. Cre/Lox recombination is a sitespecific recombinase technology and is used to delete, insert, translocate, and/or invert at
specific sites in DNA. This was made possible by researchers that were able to introduce
bacteriophage recombination systems into mammalian cells, typically a mouse or rat
(Sauer & Henderson, 1988). The enzyme “Cre recombinase” uses a mechanism that cuts
one of the DNA strands between two DNA recognition sites (loxP sites), carries out the
specific recombination event, and then reanneal the strand. Cre inducible viral vector
technology has been used to insert chanelrhodopsin DNA into sites that also produce the
enzyme tyrosine hydroxylase (Madisen et al., 2012). This specific targeting system
effectively expresses chanelrhodopsin on only catecholaminergic neurons (epinephrine,
norepinephrine, and dopamine).
In order to activate ChR2, 470 nm (blue) wavelengths of light must be pulsed
onto it (Zhang et al., 2010). As mentioned previously, Bass et al. (2003) discovered that
250 light pulses at 5 Hz directed into the ventral tegmental area of experimental animals
would increase dopamine in the rat’s nucleus accumbens. The researchers used fast-scan
cyclic voltammetry to confirm dopamine concentration levels. This data collection tool
utilizes carbon-fiber microelectrodes to detect dopamine and numerous other
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neurotransmitter concentrations. The experiment also established that ethanol
consumption would significantly drop during periods of increased dopamine activity.
Researchers have recently used optogenetic tools to delve into general anxiety
disorder (GAD), which has long been a chronic and recurrent mental health issue with
high prevalence (Kessler, 2009). Kessler describes GAD as disproportionate worries in
the lack of urgent threats. GAD has a 28% lifetime prevalence, and a high concordance
rate with other mental illnesses that display anxiety. Twin studies (Roy, 1995) have
shown that a significant portion of patients inflicted by GAD also develop major
depression (MD). A study using functional magnetic resonance imaging (fMRI)
technology has shown that amygdala activity plays a role in anxiety (Etkin, 2009). The
study concludes that decreased oxygen levels in the amygdala are correlated with GAD;
the fMRI finding still lacks more precise details, such as cell type. At Stanford
University, a study used optogenetics to excite basolateral amygdala glutamate terminals
in the central terminal of the amygdala. Excitation of these neurons would increase
anxiety and the inverse action, inhibition of these neurons, would reduce anxiety (Tye et
al., 2011). Behavioral assessment of animal models in conjunction with optogenetics has
given researchers a more transparent glimpse into mental health.
GAD has been the focus of several animal behavioral assessments. Two such
assessments used in the previously mentioned study (Tye et all, 2011), are named the
elevated-plus maze and open-field test. The elevated-plus maze consists of a plus shaped
raised platform in which two of the arms have high walls. It is believed that rodents will
spend more time in the exposed area when they are less stressed. A reduction in stress, as
measured through increased time spent in the open arms of the elevated-plus maze, has
been demonstrated in rodents who have been given pharmacological agents designed to
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reduce stress (Fernandes & File, 1996). Scientists knew that these anti-anxiety drugs
would reduce anxiety in humans, but the mechanism of action remained unknown.
Major depressive disorder is characterized as a persistent low mood accompanied
by loss of pleasure in customarily enjoyable activities. Another way to look at major
depressive disorder is that an individual with depression is less motivated to escape
stressors compared to a healthy individual. Lack of motivation has been emulated in
animal models with the tail suspension test. In the tail suspension test, healthy mice are
restrained by their tail and will struggle to get away; ‘depressed’ mice will not. The
causes of depression are complex and multiple brain regions, as well as different classes
of neurotransmitters, have been linked to the disorder. Optogenetics has been used to
explore the underlying mechanisms as well as how anti-depressant drugs exert their
effects.
Using a mouse model of depression called chronic social defeat stress and
optogenetics, researchers determined that excitation of the medial prefrontal cortex
(medial prefrontal cortex) would produce anti-depressant effects (Covington et al., 2010).
A mouse was placed in a chamber with another aggressive mouse that caused chronic
stress. According to Covington, mice subjected to social defeat stress will have decreased
levels of the immediate early genes, c-fos, and arc; which are known to be cellular
indicators of clinical depression in humans’ postmortem. Optogenetic stimulation of the
medial prefrontal cortex would produce strong effects similar to anti-depressant
compounds and bring IEG levels to normal, without the known side effects of antidepressant drugs such as reduction in locomotor behavior and memory (Covington et al.,
2010).
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Dopaminergic neurons in the ventral tegmental area are crucial for the brains
reward circuitry, but are also important in depression. Patients with MDD exhibit
anhedonia, or an inability to enjoy pleasurable activity. Optogenetic tools and the
aforementioned chronic social defeat stress model have linked activity of specific types
of neurons in the ventral tegmental area to depression (Chaudhury et al., 2013).
Chaudhury established that stimulation of dopaminergic neurons in the ventral tegmental
area would cause an increased susceptibility to social defeat stress and anhedonia, as
measured through social avoidance and decreased sucrose preference. Furthermore, the
researchers showed that inhibition of ventral tegmental area projections would induce
resilience to stressors. These studies reveal novel neural and circuit-specific mechanisms
of depression.
Addiction, clinically known as substance dependence, is a chronic condition that
grows from repetitive drug intake that results in withdrawal symptoms once drug intake
ceases. Substances that cause dependence are thought to activate the mesocorticolimbic
pathway. As already mentioned, the ventral tegmental area in the midbrain extends to the
nucleus accumbens through the medial forebrain bundle. The ventral tegmental area also
projects to the prefrontal cortex (PFC), where additional information is integrated into the
motivated behavior. Food, water, sex, and other pleasurable daily normal activities
activate this mesocorticolimbic circuit. Simply put, drugs of abuse “hijack” this circuitry
to cause addiction. Activation of the circuit in response to drugs of abuse can be
demonstrated in animal models.
According to Tzschentke (2007) conditioned place preference is a type of
Pavlovian conditioning applied to quantify the motivational effects of objects or
experiences. A research animal is placed into a container that consists of two distinct
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chambers. Typically, the animal will receive a drug of abuse that has been known to
produce pleasurable effect in only one of the chambers. In the other chamber, the animal
receives the vehicle to act as a control. conditioned place preference has been able to
show repeatedly that the animal will develop a preference for the chamber where they
receive the drug.
Hsing-Chen Tsai (2009) implanted ChR2 into dopaminergic neurons of the
ventral tegmental area and tested animals performing in a conditioned place preference
environment. The experimental group of animals was placed in a container that had two
chambers. The first day of testing, mice received 1 hertz of optical excitation in chamber
one. The following day, mice received 50-Hz stimulation in chamber two. Mice
developed a clear preference for the chamber with 50 Hz stimulation (P < 0.001 t test; n =
13 mice). Mice would prefer a chamber with 1 Hz over no stimulation, but 50 Hz
produced the strongest preference. These findings sufficiently demonstrated that
dopamine could establish place preference.
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Rationale
This study was conducted to evaluate locomotor behavior during activation of
brain regions linked to the positive symptoms of schizophrenia and the actions of
antipsychotic drugs. This study corroborates with evidence that increased activity in
mesolimbic dopamine pathways can cause hyperactive locomotion in animals and
psychosis in humans. The basis of these findings mostly comes from electrophysiology
and pharmacological techniques. The recent development of optogenetic tools have
allowed researchers to re-examine the aforementioned notion. The recent development of
optogenetic tools allow researchers a level of specificity for cell types not previously
available…As previously mentioned, the ventral tegmental area is comprised of a wide
diversity of neurons that produce GABA, glutamate, and dopamine. When an area of
brain is electrically stimulated, all types of neurons are activated. Optogenetic tools
overcome this wide-spread activation with the use of Cre/Loxp systems, which was also
previously mentioned. The pairing of these technologies allow for the targeting of
specific neurotransmitter groups. This study used these technologies to evaluate D2
receptor antagonism in rats who had mesolimbic and mesocortical dopaminergic neurons
activated with optogenetic tools. The tools used in this study could make it easier to
evaluate the involvement of these specific cell types, in regards to behavior and the
effects of antipsychotic drugs. Questions about the causal mechanisms behind the
symptoms still remain. This study does not attempt to answer those immense questions,
instead it is a simple demonstration that light shown onto genetically modified neurons
elicits a behavioral response. This study builds the foundation for future experiments,
asking similar questions, to grow upon.
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This study used highly spatial and temporally precise tools to investigate how
neuronal activity can affect locomotor behavior. Video tracking equipment allows us to
visually track their movements, from where they traveled to their velocity to how close
they got to the walls, and other behaviors. The expectation is that they’ll be more active
with increased dopamine activity, to a certain point. There is also a record of body
temperature, which can increase when dopamine production is elevated. These studies
will allow us to specifically associate behavioral and physiological effects with activation
of dopamine neurons and allow us to examine the ability of D2 receptor antagonism to
reverse these effects or pharmacological enhancement of dopamine release to augment
these effects. This study took the first steps in using optogenetic tools for evaluating
antipsychotic drug effects.
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Methods
Subjects
All experiments were performed on adult Male Sprague Dawley rats. 10 wildtype
animals and 10 Tyrosine Hydroxylase (TH)-Cre animals were purchased from Sage
Laboratories. Surgical procedures on the animals began when they were between 350-400
g and were between 10-14 weeks old. Behavioral procedures occurred at least four weeks
after viral injection. Subjects were housed at 22-24*C with freely–available food and
water. All procedures were approved by the Northern Michigan University Institutional
Animal Care and Use Committee (IACUC #257) (see Appendix A).

Stereotactic injection and cannula implantation materials
pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA was a gift
from Karl Deisseroth (Addgene plasmid # 20298), (Image 9 Appendix B). Anesthesia,
NMU Biology department’s isoflurane vaporizer to anesthetize mice or rats. Isoflurane is
volatile and proper ventilation is needed. Nonsteroidal anti-inflammatory drug (NSAID)
Meloxicam, 1.0 mg per kg, Penicillin G, 30% Bleach in beaker, to dispose materials in
contact with virus, Lubricant eye ointment, Anti-Septic-Chlorhexidine & Ethanol, C&B
metabond, Dental cement, ~10-week old WT and TH: Cre rats, Surgical tools. Scissors,
forceps, and scalpel blades. Small animal stereotactic frame, Cannula Holder (custom
made by Kale Polkinghorne, Northern Michigan University). Programmable micro
syringe pump, 10 micro liter Hamilton micro syringe and tubing, Cotton swabs, Highspeed micro drill with charger. 0.5 mm and 0.9 mm Micro drill stainless steel burrs. 1 ml
Syringes with subcutaneous needles, Surgical suture, Heating blanket, and Epoxy glue.
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Material for optogenetic stimulation
4 channel PlexBright system driver with Radiant 2.0 and pattern generation.
Drives LEDs or Lasers; 8 digital inputs and 16 digital outputs. Includes controller, 4
colored BNC cables, Radiant 2.0 software, USB license key and electronic user guide.,
Dual LED rotary commutator with 2 Magnetically mounted compact LED modules for
use with commutator, terminating in an LC connector for use with an LC patch cable.
Blue, 465nm, 300mA max current. 2 200/230µm fibers; LC connector to compact LED
module; LC ferrule with polished tip; 1 m length with stainless steel jacketing LC-LC
coupler, Bronze mating sleeves, Refractive gel, and an Optical cleaning kit with cleaning
solution, lint free wipes, and lens paper. Light Measurement Kit; includes ThorLabs
PM100D Digital optical power meter with 4-inch LCD display & USB interface;
ThorLabs S140C integrating sphere photodiode optical power sensor, 350-1100 nm, 1
µW-500 mW; and Plexon PlexBright adaptor set.
Materials for behavioral assessment
Noldus Ethovision Hardware and XT 7.0 software (Noldus Information
Technology, Leesburg, VA), PC, Locomotor Enclosure, and Infrared Thermometer
Apparatus
The locomotor enclosure was a wooden box with four separate identical
compartments measuring 45.72 cm long x 45.72 cm wide and 27 cm tall. The side walls
were painted white and a black rubber mat was placed in the bottom to provide a contrast
in color to better track movement. An infrared thermometer (model # 153IRB, Bioseb,
Pinellas Park, FL) was used to collect temperature from the base of the animal’s tail.
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Drugs
Saline, raclopride, and amphetamine were administered subcutanteously.
intraperitoneally in 1.0 mg/kg, 0.1, or 0.3 mg/kg doses. Drugs were dissolved in a
ringer’s solution containing 145 mM NaCl 2.7 mM KCl, 1.0 mM MgCl2, and 1.2 mM
CaCl2. Drugs were purchased from Sigma Aldrich.

Procedures
Proper target coordinates (Paxinos, 1997) were confirmed prior to when the
experimental animals underwent surgery. Image 1 (Appendix B) was processed and
collected by Dr. Erich Ottem; he utilized an Olympus Fluoview confocal laser-scanning
microscope here at Northern Michigan University. This image demonstrated proper
needle placement in the ventral tegmental area, the visible needle tract aligned with the
same coordinates described in Image 2 (Appendix B).

Implant Testing and Fabrication
The fiber optic light guides were custom made in-house, following protocols from
ThorLabs’s Guide to Connectorization and Polishing Optical Fibers, this PDF is freely
available online (ThorLabs, 2006). After fabrication, all implants were tested to ensure
proper assembly and that enough light would be emitted. When 50 mWs were pulsed
from a LED, each implant used during experiments emitted at least 5 mWs. 5 mWs is
above the activation threshold for ChR2 and this was deemed sufficient for implantation.
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At this activation strength and wavelength, light was emitted in a cone shape that did not
extend past the ventral tegmental area (assuming the implantation hit the coordinates).
Surgical Procedures
The procedures to inject 0.5 ul of the viral vector and to implant light guides that
terminate at the same coordinates were similar to procedures described by Deisseroth
(2011) and Pehrson et al. (2012). First, all surgical tools were cleaned and sterilized. The
surgical table was disinfected with 70% ethanol. Aseptic conditions are necessary to
prevent infection and to guarantee survival for the following weeks. Underneath a sterile
absorption gauze, a heating pad was placed and kept at 35˚ C. Then the AAV was thawed
on ice; AAV can be kept at 4 Cº for 1 month. Meloxicam (1.0 mg/kg) and penicillin (0.25
ml) were given subcutaneously to minimize pain and discomfort, it is important to
administer one hour before causing pain and to prevent infection. Rats were anesthetized
using 1.5-2.5% isoflurane. The injection needle was slowly lowered to the proper depth
(A/P -4.9mm, M/L +2.1mm; D/V -8.6mm; Paxinos et al., 1997) and the virus was
injected the virus with a microsyringe through an internal cannula at a rate of 0.1 ul/min.
We waited one additional minute to allow time for the virus to spread, and then slowly
removed needle. Next, the light guide was placed in the cannula holder and slowly
lowered into the brain to the same coordinates as the injection needle. Then the skull was
dried with cotton swabs. After it was dry, a thin layer of C&B metabond was applied to
the skull and around the cannula pedestal to fix the pedestal in place. Both groups
(THCre and WT) underwent the surgery and viral injection, in order for the WT rats to
serve as controls. Follow up injections of 0.5 mg/kg were given every 24 hours for the
first three days of recovery. Behavioral testing began four weeks after surgical
procedures.
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Behavioral Procedures
The rats were brought into the behavioral testing room 30 minutes prior to video
recording; which was comprised of three five-minute long tracking sessions per animal.
Ten minutes before a recording session, the rat would be connected to the fiber optic
cable. Each experiment was designed in an A/B/A pattern (baseline/treatment/baseline),
meaning that the first five-minute session they would receive no light, the second 5minute session began with 50 seconds of light pulses from the blue LED diodes, and the
final five-minutes there was no light. At the end of each 5-minute session, body
temperature would be recorded. The first experiment was conducted to determine if light
would produce a significant increase of movement and/or an increase of body
temperature while the animals received no drugs. The second experiment included
treatment with amphetamine. The third and final experiment included treatment with
raclopride.

Data Analysis
The dependent variables measured for the locomotor test were total cm travelled
and body temperature. A repeated measures one-way analysis of variance was used to
analyze the effects of light and each drug on each measure. Any significance was
analyzed further with a Tukey’s multiple comparisons test in order to determine which
group means were significant from each other. Missing data points were filled in with the
group mean. All analyses were conducted using GraphPad Prism for Windows Version
6.0 (GraphPad Software, La Jolla, CA).
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Results
Locomotor Behavior Experiments
Total cm travelled: 5 minute trials
Figure 3 represents the mean path length for 5 minutes before (M = 1506.55, SD
= 493.56), during (M = 1893.16, SD = 705.12), and after trials of light pulses into the
transgenic rats. Pulses of light significantly increased path length F (2, 16) = 6.284, p <
0.01. A significant increase of path length was found between the “during” session
compared to the “before” or “after” trials.

Figure 4 represents the mean path length in 5 minutes, before (M = 1560.92, SD =
377.17) and during (M = 1636.35, SD = 502.65) and after trials of light pulses in wild
type rats. Pulses of light had no significant effect on path length in the wildtype rats, F(2,
12) = 0.09793, p = 0.9074.
Body Temperature
Figure 5 represents the mean body temperature, which was assessed at the end of
each locomotor activity trial, for the in transgenic rats. Pulses of light significantly
increased body temperature F (2, 16) = 21.78, p < 0.01. A significant increase of body
temperature was found between the “during” session compared to the “before” or “after”
trials.

Figure 6 represents the mean body temperature for the wild type rats. Pulses of
light had no significant effect on body temperature F (2, 12) = 0.9141, p = 0.42.
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Amphetamine Experiments

Figure 7 represents the mean path length in 5 minutes, before and during trials of
light pulses in transgenic rats during saline and amphetamine treatments. Amphetamine
significantly increased path length F (3, 21) = 67, p < 0.01. A significant path length
increase was found between the “during” session compared to the “before” or “after”
trials.
Figure 8 represents the mean body temperaturefor the transgenic rats treated with
amphetamine. Pulses of light had a significant increase on body temperature F (3, 21) =
5.2, p < 0.01. Amphetamine treatment had no significant effect on body temperature.
Raclopride Experiments
Figure 9 represents the mean path length in 5 minutes, before and during trials of
light pulses in transgenic rats during saline and raclopride 0.1 mg/kg and 0.3 mg/kg
treatments. Significant differences across the testing conditions was found, F (5, 30) =
3.0, P < 0.05. Post hoc results demonstrated that there was significant path length
increase was found between the means of saline treatments and 0.1 mg/kg raclopride+
treatments. There was no significant increase found between saline treatments and 0.3
mg/kg+.
Figure 10 represents the mean body temperature for the transgenic rats during
saline and raclopride 0.1 mg/kg and 0.3 mg/kg treatments. 0.3 mg/kg raclopride treatment
compared to saline significantly decreased body temperature F (5, 35) = 6.1, p < 0.01.
Post hoc results showed a significant decrease in body temperature at 0.1 mg/kg
treatment and a significant increase from 0.1 mg/kg to 0.3 mg/kg.
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All figures represent the mean plus the standard error of the mean.
“+” =trial with pulses of light and “*” = significance.
Figure 3: THCre Baseline/Distance Travelled
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Figure 3 represents the post hoc results comparing means for the total cm travelled in 5
minutes, before, during, and after trials of light pulses into the transgenic rats. Treatment
with light pulses significantly increased the path length *p < 0.05 versus “before” and
+p<0.05 versus “after.”
Figure 4: Wild Type Control Group/Distance Travelled
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Figure 4 represents the mean for the total cm travelled in 5 minutes before, during, and
after light pulses into the WT rats. Treatment of light pulses into wild type rats had no
significant effect.
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Figure 5: THCre Baseline/Body Temperature
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Figure 5 represents the mean for body temperature before, during, and after trials of light
pulses into transgenic rats. Treatment with light pulses significantly increased body
temperature *p < 0.05 versus “before” and +p<0.05 versus “after.”
.
Figure 6: Wild Type Temperature/Control Group
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Figure 6 represents the mean for body temperature travelled before, during, and after
trials of light pulses into wild type rats. Treatment with light pulses had no significant
effect on body temperature.
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Figure 7: Amphetamine and Distance Travelled
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Figure 7 represents the mean for the total cm travelled in 5 minutes, before, during, and
after trials of light pulses into saline and amphetamine treated transgenic rats. Treatment
with amphetamine significantly increased the path length *p < 0.05 versus “Saline” and
+p<0.05 versus “1.0mg/kg”.
“+” = Light

Figure8: Amphetamine and Temperature
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Figure 8 represents the mean for body temperature before, during, and after trials of light
pulses into saline and amphetamine treated transgenic rats. Treatment with light pulses
significantly increased body temperature *p < 0.05 versus “Saline+” and +p<0.05 versus
“1.0mg/kg+”.
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“+” = Light

Figure 9: Raclopride and Distance Travelled
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Figure 9 represents the mean path length in 5 minutes, before and during trials of
light pulses in transgenic rats during saline and raclopride 0.1 mg/kg and 0.3 mg/kg
treatments.
Figure 10: Raclopride and Temperature
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Figure 10 represents the mean body temperature for the transgenic rats during
saline and raclopride 0.1 mg/kg and 0.3 mg/kg treatments.
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Discussion
This study explored the use of optogenetic tools to better understand treatments
used for schizophrenia. The “positive” symptoms (e.g., hallucinations, paranoia, etc.) of
schizophrenia may come from overexpression of dopamine in mesolimbic dopamine
neurons. Positive symptoms can be produced in healthy volunteers treated with
amphetamine, a psychostimulant drug and dopamine releaser. Conversely, antipsychotic
drugs may reduce positive symptoms by blocking receptors for dopamine. This study
used optogenetics to explore how drugs that alter dopamine neurotransmission might
alter behaviors occurring from activation of mesolimbic dopamine neurons in the ventral
tegmental area. Light-induced activation of dopaminergic neurons in the ventral
tegmental area in male rats produced a significant increase in total distance traveled in an
open field and body temperature. Animals treated with amphetamine, a dopamine
releaser, also had a significant increase in total distance travelled and body temperature.
Light-induced activation of dopaminergic neurons during trials of amphetamine did not
show a significant change, it is logical to think amphetamine depleted neurons of
dopamine. A D2/3 receptor antagonist did block these effects. These results demonstrate
that selective activation of mesolimbic dopamine neurons produces effects similar to
amphetamine. Further, they coincide with previous findings that used different research
techniques to link amphetamine’s effects to mesolimbic dopamine neurons. This proof of
concept study was the first to be conducted at Northern Michigan University, and also
serves as the first to report the effects of an antipsychotic drugs used with optogenetic
techniques. A significant amount of trial and error managed to successfully implement
this research tool for future NMU students to utilize.
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Optogenetic tools have increased locomotor behavior before, optogenetics was
recently used to selectively activate neurons expressing Calcium/calmodulin-dependent
protein kinase type II alpha chain (Commonly known as CaMKIIa) in the ventral
tegmental area of Sprague Dawley rats (Guo et al., 2014). CamKIIa is an enzyme is
crucial for calcium signaling involved with hippocampal long-term potentiation and
spatial learning. Guo (2014) demonstrated that excitation with light into the ventral
tegmental area would increase activity in free roaming tasks.
Pulses of light significantly increased path length in the transgenic rats. As
previously shown, increased dopamine concentrations can cause an increase of activity
within the sympathetic nervous system (Tritsch, Ding, & Sabatini, 2012). The mean for
the total cm travelled in 5 minutes, before and during. Adding to this increase of
locomotor behavior, pulses of light significantly increased body temperature. A
significant increase of body temperature was found between the means of the session
with light compared to before and after. As mentioned earlier, dopamine antagonists have
been shown to cause hypothermia (Chaperon et al., 2003). This study demonstrated that
dopamine plays an intimate role with body temperature regulation.
The control group was comprised of wild type Sprague Dawley rats that were
bred and raised from the same strain as the transgenic rats and in the same location. As
expected, Pulses of light had no significant effect on path length.
In five minute trials of the testing sessions, amphetamine at a 1.0 mg/kg dose
produced a significant increase of distance travelled compared to baseline data. These
results are comparable to previous experiments (Westerink et al., 2001) (Griffith et al.,
1972) (Lieberman et al., 1987) (Laruelle et al., 1996).

38

This study raises several intriguing research questions, such as what would occur
when a treatment of a D1 receptor antagonist treatment is implemented? Or an atypical 5HT receptor antagonist? What would these drugs do to activity? The addition of
electrophysiological. Fast-scan cyclic voltammetry, or microdialysis equipment would be
immensely helpful in answering more detailed questions. Optogenetics is commonly
paired with these technologies and allow researchers to more thoroughly understand
neuronal communications. As previously mentioned, fast-scan cyclic voltammetry could
report specific neurotransmitter concentrations in regions connected to a region that is
being activated with optogenetics.
Optogenetics has been used in a variety of animals, rodents mostly, but also
zebrafish (Douglass et all, 2008), fruit flies (Drosophila melanogaster) (Lima &
Miesenböck, 2005), nematode worms (Caenorhabditis elegans) (Blaxter, 2010) and nonhuman primates (Han et al., 2011). With a research tool as powerful as optogenetics, the
logical next step is producing it in humans for therapeutic effects on mental illnesses.
Chow and Boyden (2013) recently published an article with a discussion of obstacles that
would have to be overcome to bring optogenetics to clinical trials. The largest issue is the
use of viral vectors and the subsequent immune response (Chow & Boyden, 2013).
Human opsins, such as rhodopsin in the human eye, could be inserted into neurons, but
these cells are slower than the microbial ones currently in use for optogenetics. Gene
therapy is advancing every day and it is possible that someday humans could reap the
benefits of the precision actions optogenetics has to offer.
Even if optogenetics remains as purely a research tool and does not give rise to
beneficial effects directly in our species, it has still offered humans an unparalleled look
into the function and dysfunction of the nervous system. Optogenetics has been adopted
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in laboratories around the world and has enabled scientists to increase or decrease the
activity of exclusive brain regions on command. Great insight has been obtained through
the use of optogenetics and a great deal more has yet to be discovered.

40

References
Andreasen, N. C. (1989). The American Concept of Schizophrenia. Schizophrenia Bulletin,
15(4), 519–531. http://doi.org/10.1093/schbul/15.4.519
Association, A. P. (2013). Diagnostic and Statistical Manual of Mental Disorders (DSM-5®).
American Psychiatric Pub.
Bass, C. E., Grinevich, V. P., Gioia, D., Day-Brown, J. D., Bonin, K. D., Stuber, G. D., …
Budygin, E. A. (2013). Optogenetic stimulation of VTA dopamine neurons reveals that
tonic but not phasic patterns of dopamine transmission reduce ethanol selfadministration. Frontiers in Behavioral Neuroscience, 7.
http://doi.org/10.3389/fnbeh.2013.00173
Beier, K. T., Steinberg, E. E., DeLoach, K. E., Xie, S., Miyamichi, K., Schwarz, L., … Luo, L.
(2015). Circuit Architecture of VTA Dopamine Neurons Revealed by Systematic InputOutput Mapping. Cell, 162(3), 622–634. http://doi.org/10.1016/j.cell.2015.07.015
Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K., & Seitelberger, F. (1973).
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological
and neurochemical correlations. Journal of the Neurological Sciences, 20(4), 415–455.
Blau, H. M., & Springer, M. L. (1995). Muscle-mediated gene therapy. New England Journal
of Medicine, 333(23), 1554–1556.
Blum, K., Oscar-Berman, M., Badgaiyan, R. D., Palomo, T., & Gold, M. S. (2014).
Hypothesizing dopaminergic genetic antecedents in schizophrenia and substance seeking
behavior. Medical Hypotheses, 82(5), 606–614.
http://doi.org/10.1016/j.mehy.2014.02.019

41

Boulay, D. (1999). Dopamine D3 receptor agonists produce similar decreases in body
temperature and locomotor activity in D3 knock-out and wild-type mice.
Neuropharmacology, 38(4), 555–565. http://doi.org/10.1016/S0028-3908(98)00213-5
Boyden, E. (2011). A history of optogenetics: the development of tools for controlling brain
circuits with light. F1000 Biology Reports, 3. http://doi.org/10.3410/B3-11
Buchanan, R. W., Javitt, D. C., Marder, S. R., Schooler, N. R., Gold, J. M., McMahon, R. P.,
… Carpenter, W. T. (2007). The Cognitive and Negative Symptoms in Schizophrenia
Trial (CONSIST): The Efficacy of Glutamatergic Agents for Negative Symptoms and
Cognitive Impairments. American Journal of Psychiatry, 164(10), 1593–1602.
http://doi.org/10.1176/appi.ajp.2007.06081358
Carlsson, A., & Lindqvist, M. (1963). Effect of Chlorpromazine or Haloperidol on Formation
of 3-Methoxytyramine and Normetanephrine in Mouse Brain. Acta Pharmacologica et
Toxicologica, 20(2), 140–144. http://doi.org/10.1111/j.1600-0773.1963.tb01730.x
Carlsson, A., Lindqvist, M., & Magnusson, T. (1957). 3,4-Dihydroxyphenylalanine and 5Hydroxytryptophan as Reserpine Antagonists. Nature, 180(4596), 1200–1200.
http://doi.org/10.1038/1801200a0
Carr, D. B., & Sesack, S. R. (2000). GABA-containing neurons in the rat ventral tegmental
area project to the prefrontal cortex. Synapse, 38(2), 114–123.
http://doi.org/10.1002/1098-2396(200011)38:2<114::AID-SYN2>3.0.CO;2-R
Chang, C.-K., Hayes, R. D., Perera, G., Broadbent, M. T. M., Fernandes, A. C., Lee, W. E., …
Stewart, R. (2011). Life Expectancy at Birth for People with Serious Mental Illness and
Other Major Disorders from a Secondary Mental Health Care Case Register in London.
PLoS ONE, 6(5), e19590. http://doi.org/10.1371/journal.pone.0019590

42

Chaperon, F., Tricklebank, M. D., Unger, L., & Neijt, H. C. (2003). Evidence for regulation of
body temperature in rats by dopamine D2 receptor and possible influence of D1 but not
D3 and D4 receptors. Neuropharmacology, 44(8), 1047–1053.
http://doi.org/10.1016/S0028-3908(03)00113-8
Clemens, J. A., Smalstig, E. B., & Sawyer, B. D. (1974). Antipsychotic drugs stimulate
prolactin release. Psychopharmacologia, 40(2), 123–127.
http://doi.org/10.1007/BF00421361
Crick, F. H. (1979). Thinking about the brain. Scientific American, 241(3), 219–232.
Crow, T. J. (1980). Molecular pathology of schizophrenia: more than one disease process?
British Medical Journal, 280(6207), 66–68.
Davis, K. (1991, November). Dopamine in Schizophrenia: A Review and Reconceptualization
- ProQuest. Retrieved January 22, 2016, from
http://search.proquest.com/openview/31efea8c61ba214d7dd3276f0c8e0cb5/1?pqorigsite=gscholar
Deisseroth, K. (2011). Optogenetics. Nature Methods, 8(1), 26–29.
http://doi.org/10.1038/nmeth.f.324
Delay, J., Deniker, P., & Harl, J. M. (1952). [Therapeutic use in psychiatry of phenothiazine of
central elective action (4560 RP)]. Annales Médico-Psychologiques, 110(2 1), 112–117.
Diaz, J. (1996). How Drugs Influence Behavior: A Neurobehavioral Approach (1 edition).
Upper Saddle River, N.J: Prentice Hall College Div.
Dixon, L., Weiden, P., Delahanty, J., Goldberg, R., Postrado, L., Lucksted, A., & Lehman, A.
(2000). Prevalence and correlates of diabetes in national schizophrenia samples.
Schizophrenia Bulletin, 26(4), 903–912.

43

Drugs and Human Performance FACT SHEETS - Methamphetamine (and Amphetamine).
(n.d.). Retrieved March 11, 2016, from
http://www.nhtsa.gov/people/injury/research/job185drugs/methamphetamine.htm
Egan, M. F., Goldberg, T. E., Kolachana, B. S., Callicott, J. H., Mazzanti, C. M., Straub, R. E.,
… Weinberger, D. R. (2001). Effect of COMT Val108/158 Met genotype on frontal lobe
function and risk for schizophrenia. Proceedings of the National Academy of Sciences,
98(12), 6917–6922. http://doi.org/10.1073/pnas.111134598
Emsley, R., Niehaus, D. J. H., Koen, L., Oosthuizen, P. P., Turner, H. J., Carey, P., … Murck,
H. (2006). The effects of eicosapentaenoic acid in tardive dyskinesia: A randomized,
placebo-controlled trial. Schizophrenia Research, 84(1), 112–120.
http://doi.org/10.1016/j.schres.2006.03.023
Farde, L., Nordström, A.-L., Wiesel, F.-A., Pauli, S., Halldin, C., & Sedvall, G. (1992).
Positron emission tomographic analysis of central D1 and D2 dopamine receptor
occupancy in patients treated with classical neuroleptics and clozapine: relation to
extrapyramidal side effects. Archives of General Psychiatry, 49(7), 538–544.
Foster, K. W., & Smyth, R. D. (1980). Light Antennas in phototactic algae. Microbiological
Reviews, 44(4), 572–630.
Friston, K. J., Liddle, P. F., Frith, C. D., Hirsch, S. R., & Frackowiak, R. S. J. (1992). The Left
Medial Temporal Region and Schizophrenia: A Pet Study. Brain, 115(2), 367–382.
http://doi.org/10.1093/brain/115.2.367
Frith, C. D. (1987). The positive and negative symptoms of schizophrenia reflect impairments
in the perception and initiation of action. Psychological Medicine, 17(03), 631–648.
http://doi.org/10.1017/S0033291700025873

44

German, D. C., & Manaye, K. F. (1993). Midbrain dopaminergic neurons (nuclei A8, A9, and
A10): three-dimensional reconstruction in the rat. The Journal of Comparative
Neurology, 331(3), 297–309. http://doi.org/10.1002/cne.903310302
Gold, J. M., Strauss, G. P., Waltz, J. A., Robinson, B. M., Brown, J. K., & Frank, M. J. (2013).
Negative Symptoms of Schizophrenia Are Associated with Abnormal Effort-Cost
Computations. Biological Psychiatry, 74(2), 130–136.
http://doi.org/10.1016/j.biopsych.2012.12.022
Gray, J. A., Joseph, M. H., Hemsley, D. R., Young, A. M. J., Warburton, E. C., Boulenguez,
P., … Feldon, J. (1995). The role of mesolimbic dopaminergic and retrohippocampal
afferents to the nucleus accumbens in latent inhibition : implications for schizophrenia. In
Behavioural brain research (Vol. 71, pp. 19–31). Elsevier. Retrieved from
http://cat.inist.fr/?aModele=afficheN&cpsidt=2954788
Griffith JD, Cavanaugh J, Held J, & Oates JA. (1972). Dextroamphetamine: Evaluation of
psychomimetic properties in man. Archives of General Psychiatry, 26(2), 97–100.
http://doi.org/10.1001/archpsyc.1972.01750200001001
Han, X. (2012). In Vivo Application of Optogenetics for Neural Circuit Analysis. ACS
Chemical Neuroscience, 3(8), 577–584. http://doi.org/10.1021/cn300065j
Hirayasu, Y., Shenton, M. E., Salisbury, D. F., Dickey, C. C., Fischer, I. A., Mazzoni, P., …
McCarley, R. W. (1998). Lower left temporal lobe MRI volumes in patients with firstepisode schizophrenia compared with psychotic patients with first-episode affective
disorder and normal subjects. The American Journal of Psychiatry, 155(10), 1384–1391.
http://doi.org/10.1176/ajp.155.10.1384

45

Howes, O. D., & Kapur, S. (2009). The Dopamine Hypothesis of Schizophrenia: Version III—
The Final Common Pathway. Retrieved February 15, 2016, from
http://schizophreniabulletin.oxfordjournals.org
Jankowsky, J. L., Slunt, H. H., Ratovitski, T., Jenkins, N. A., Copeland, N. G., & Borchelt, D.
R. (2001). Co-expression of multiple transgenes in mouse CNS: a comparison of
strategies. Biomolecular Engineering, 17(6), 157–165.
Kempadoo, K. A., Tourino, C., Cho, S. L., Magnani, F., Leinninger, G.-M., Stuber, G. D., …
Bonci, A. (2013). Hypothalamic Neurotensin Projections Promote Reward by Enhancing
Glutamate Transmission in the VTA. Journal of Neuroscience, 33(18), 7618–7626.
http://doi.org/10.1523/JNEUROSCI.2588-12.2013
Kendler, K. S., & Diehl, S. R. (1993). The genetics of schizophrenia: a current, geneticepidemiologic perspective. Schizophrenia Bulletin, 19(2), 261–285.
Knapp, M., Mangalore, R., & Simon, J. (2004). The Global Costs of Schizophrenia.
Schizophrenia Bulletin, 30(2), 279–293.
Kuhn, R., & Cahn, C. H. (2004). Eugen Bleuler’s Concepts of Psychopathology. History of
Psychiatry, 15(3), 361–366. http://doi.org/10.1177/0957154X04044603
Laruelle, M., Abi-Dargham, A., Dyck, C. H. van, Gil, R., D’Souza, C. D., Erdos, J., … Innis,
R. B. (1996). Single photon emission computerized tomography imaging of
amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proceedings
of the National Academy of Sciences, 93(17), 9235–9240.
Laviolette, S. R. (2007). Dopamine Modulation of Emotional Processing in Cortical and
Subcortical Neural Circuits: Evidence for a Final Common Pathway in Schizophrenia?
Schizophrenia Bulletin, 33(4), 971–981. http://doi.org/10.1093/schbul/sbm048

46

Lieberman, J. A., Kane, J. M., & Alvir, J. (1987). Provocative tests with psychostimulant
drugs in schizophrenia. Psychopharmacology, 91(4), 415–433.
http://doi.org/10.1007/BF00216006
Lim, H.-S., Kim, S. J., Noh, Y.-H., Lee, B. C., Jin, S.-J., Park, H. S., … Kim, S. E. (2012).
Exploration of Optimal Dosing Regimens of Haloperidol, a D2 Antagonist, via Modeling
and Simulation Analysis in a D2 Receptor Occupancy Study. Pharmaceutical Research,
30(3), 683–693. http://doi.org/10.1007/s11095-012-0906-2
Lin, J. Y. (2011). A user’s guide to channelrhodopsin variants: features, limitations and future
developments. Experimental Physiology, 96(1), 19–25.
http://doi.org/10.1113/expphysiol.2009.051961
Madisen, L., Mao, T., Koch, H., Zhuo, J., Berenyi, A., Fujisawa, S., … Zeng, H. (2012). A
toolbox of Cre-dependent optogenetic transgenic mice for light-induced activation and
silencing. Nature Neuroscience, 15(5), 793–802. http://doi.org/10.1038/nn.3078
Melmed, S., Casanueva, F. F., Hoffman, A. R., Kleinberg, D. L., Montori, V. M., Schlechte, J.
A., & Wass, J. A. H. (2011). Diagnosis and Treatment of Hyperprolactinemia: An
Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology &
Metabolism, 96(2), 273–288. http://doi.org/10.1210/jc.2010-1692
Meltzer, H. Y. (1989). Clinical studies on the mechanism of action of clozapine: the
dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology, 99 Suppl, S18–
27.
Meltzer, H. Y., & Stahl, S. M. (1976). The dopamine hypothesis of schizophrenia: A review.
Schizophrenia Bulletin, 2(1), 19–76.
Mørk, A., Pehrson, A., Brennum, L. T., Nielsen, S. M., Zhong, H., Lassen, A. B., … Stensbøl,
T. B. (2012). Pharmacological Effects of Lu AA21004: A Novel Multimodal Compound
47

for the Treatment of Major Depressive Disorder. Journal of Pharmacology and
Experimental Therapeutics, 340(3), 666–675. http://doi.org/10.1124/jpet.111.189068
Nagel, G. (2002). Channelrhodopsin-1: A Light-Gated Proton Channel in Green Algae.
Science, 296(5577), 2395–2398. http://doi.org/10.1126/science.1072068
Nagel, G., Szellas, T., Huhn, W., Kateriya, S., Adeishvili, N., Berthold, P., … Bamberg, E.
(2003). Channelrhodopsin-2, a directly light-gated cation-selective membrane channel.
Proceedings of the National Academy of Sciences of the United States of America,
100(24), 13940–13945. http://doi.org/10.1073/pnas.1936192100
nmeth.f.321.pdf. (n.d.).
Passamonti, L., Terracciano, A., Riccelli, R., Donzuso, G., Cerasa, A., Vaccaro, M., …
Quattrone, A. (2015). Increased functional connectivity within mesocortical networks in
open people. NeuroImage, 104, 301–309.
http://doi.org/10.1016/j.neuroimage.2014.09.017
Paxinos, G. (1997). The Rat Brain in Stereotaxic Coordinates–The New Coronal Set, 5th Edn.
Retrieved March 14, 2016, from
https://www.researchgate.net/publication/236306584_The_Rat_Brain_in_Stereotaxic_Co
ordinates-The_New_Coronal_Set_5th_Edn
Paz, R. D., Tardito, S., Atzori, M., & Tseng, K. Y. (2008). Glutamatergic dysfunction in
schizophrenia: from basic neuroscience to clinical psychopharmacology. European
Neuropsychopharmacology: The Journal of the European College of
Neuropsychopharmacology, 18(11), 773–786.
http://doi.org/10.1016/j.euroneuro.2008.06.005
Peled, A. (2011). Optogenetic neuronal control in schizophrenia. Medical Hypotheses, 76(6),
914–921. http://doi.org/10.1016/j.mehy.2011.03.009
48

Philip, S. (1980). Brain dopamine receptors. - PubMed - NCBI. Retrieved March 29, 2016,
from http://ezpolson.nmu.edu:6207/pubmed/6117090
Picchioni, M. M., & Murray, R. M. (2007). Schizophrenia. BMJ : British Medical Journal,
335(7610), 91–95. http://doi.org/10.1136/bmj.39227.616447.BE
Pierre, D. J. M. (2012). Extrapyramidal Symptoms with Atypical Antipsychotics. Drug Safety,
28(3), 191–208. http://doi.org/10.2165/00002018-200528030-00002
Post, R. M., Jimerson, D. C., Bunney, W. E., & Goodwin, F. K. (1980). Dopamine and mania:
behavioral and biochemical effects of the dopamine receptor blocker pimozide.
Psychopharmacology, 67(3), 297–305.
Romanides, A. J., Duffy, P., & Kalivas, P. W. (1999). Glutamatergic and dopaminergic
afferents to the prefrontal cortex regulate spatial working memory in rats. Neuroscience,
92(1), 97–106. http://doi.org/10.1016/S0306-4522(98)00747-7
Saha, S., Chant, D., Welham, J., & McGrath, J. (2005). A Systematic Review of the
Prevalence of Schizophrenia. PLoS Med, 2(5), e141.
http://doi.org/10.1371/journal.pmed.0020141
Sakurai, Y., & Sugimoto, S. (1985). Effects of lesions of prefrontal cortex and dorsomedial
thalamus on delayed go/no-go alternation in rats. Behavioural Brain Research, 17(3),
213–219. http://doi.org/10.1016/0166-4328(85)90045-2
Sauer, B., & Henderson, N. (1988). Site-specific DNA recombination in mammalian cells by
the Cre recombinase of bacteriophage P1. Proceedings of the National Academy of
Sciences of the United States of America, 85(14), 5166–5170.
Saunders, A., Johnson, C. A., & Sabatini, B. L. (2012). Novel recombinant adeno-associated
viruses for Cre activated and inactivated transgene expression in neurons. Frontiers in
Neural Circuits, 6. http://doi.org/10.3389/fncir.2012.00047
49

Schotte, A., Janssen, P. F., Gommeren, W., Luyten, W. H., Van Gompel, P., Lesage, A. S., …
Leysen, J. E. (1996). Risperidone compared with new and reference antipsychotic drugs:
in vitro and in vivo receptor binding. Psychopharmacology, 124(1-2), 57–73.
Schotte, A., Janssen, P. F., Megens, A. A., & Leysen, J. E. (1993). Occupancy of central
neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo
by quantitative autoradiography. Brain Research, 631(2), 191–202.
Seeman, P. (2002). Atypical antipsychotics: mechanism of action. Canadian Journal of
Psychiatry. Revue Canadienne De Psychiatrie, 47(1), 27–38.
Shenton, M. E., Dickey, C. C., Frumin, M., & McCarley, R. W. (2001). A review of MRI
findings in schizophrenia. Schizophrenia Research, 49(1-2), 1–52.
Smits, S. M., Terwisscha van Scheltinga, A. F., van der Linden, A. J. A., Burbach, J. P. H., &
Smidt, M. P. (2004). Species differences in brain pre-pro-neurotensin/neuromedin N
mRNA distribution: the expression pattern in mice resembles more closely that of
primates than rats. Brain Research. Molecular Brain Research, 125(1-2), 22–28.
http://doi.org/10.1016/j.molbrainres.2004.03.001
Stuber, G. D., Britt, J. P., & Bonci, A. (2012). Optogenetic modulation of neural circuits that
underlie reward seeking. Biological Psychiatry, 71(12), 1061–1067.
Swanson, L. W. (1982). The projections of the ventral tegmental area and adjacent regions: A
combined fluorescent retrograde tracer and immunofluorescence study in the rat. Brain
Research Bulletin, 9(1–6), 321–353. http://doi.org/10.1016/0361-9230(82)90145-9
Tandon, R., Gaebel, W., Barch, D. M., Bustillo, J., Gur, R. E., Heckers, S., … Carpenter, W.
(2013). Definition and description of schizophrenia in the DSM-5. Schizophrenia
Research, 150(1), 3–10. http://doi.org/10.1016/j.schres.2013.05.028

50

Taylor, D., Paton, C., & Kapur, S. (2015). The Maudsley Prescribing Guidelines in
Psychiatry. John Wiley & Sons.
Toettcher, J. E., Voigt, C. A., Weiner, O. D., & Lim, W. A. (2011). The promise of
optogenetics in cell biology: interrogating molecular circuits in space and time. Nature
Methods, 8(1), 35–38. http://doi.org/10.1038/nmeth.f.326
Tritsch, N. X., Ding, J. B., & Sabatini, B. L. (2012). Dopaminergic neurons inhibit striatal
output via non-canonical release of GABA. Nature, 490(7419), 262–266.
http://doi.org/10.1038/nature11466
Tyrosine Hydroxylase (TH)-Cre Rat. (n.d.). Retrieved January 25, 2016, from
https://www.horizondiscovery.com/in-vivo-models/tyrosine-hydroxylase-th-cre-rattgra8400
Ung, K., & Arenkiel, B. R. (2012). Fiber-optic Implantation for Chronic Optogenetic
Stimulation of Brain Tissue. Journal of Visualized Experiments, (68).
http://doi.org/10.3791/50004
Van Duyne, G. D. (2001). A Structural View of Cre-loxP Site-Specific Recombination.
Annual Review of Biophysics and Biomolecular Structure, 30(1), 87–104.
http://doi.org/10.1146/annurev.biophys.30.1.87
Viggiano, D., Vallone, D., Welzl, H., & Sadile, A. G. (2002). The Naples High- and LowExcitability Rats: Selective Breeding, Behavioral Profile, Morphometry, and Molecular
Biology of the Mesocortical Dopamine System. Behavior Genetics, 32(5), 315–333.
http://doi.org/10.1023/A:1020210221156
Voskoboynik, A., Newman, A. M., Corey, D. M., Sahoo, D., Pushkarev, D., Neff, N. F., …
Weissman, I. L. (2013). Identification of a Colonial Chordate Histocompatibility Gene.
Science, 341(6144), 384–387. http://doi.org/10.1126/science.1238036
51

Wang, S., Tan, Y., Zhang, J.-E., & Luo, M. (2013). Pharmacogenetic activation of midbrain
dopaminergic neurons induces hyperactivity. Neuroscience Bulletin, 29(5), 517–524.
http://doi.org/10.1007/s12264-013-1327-x
Wellen, K. E., Hatzivassiliou, G., Sachdeva, U. M., Bui, T. V., Cross, J. R., & Thompson, C.
B. (2009). ATP-Citrate Lyase Links Cellular Metabolism to Histone Acetylation.
Science, 324(5930), 1076–1080. http://doi.org/10.1126/science.1164097
Wenzel, J. M., Rauscher, N. A., Cheer, J. F., & Oleson, E. B. (2015). A Role for Phasic
Dopamine Release within the Nucleus Accumbens in Encoding Aversion: A Review of
the Neurochemical Literature. ACS Chemical Neuroscience, 6(1), 16–26.
http://doi.org/10.1021/cn500255p
Westerink, B. H. C., Kawahara, Y., De Boer, P., Geels, C., De Vries, J. B., Wikström, H. V.,
… Long, S. K. (2001). Antipsychotic drugs classified by their effects on the release of
dopamine and noradrenaline in the prefrontal cortex and striatum. European Journal of
Pharmacology, 412(2), 127–138. http://doi.org/10.1016/S0014-2999(00)00935-3
Westerink, B. H., Kwint, H. F., & deVries, J. B. (1996). The pharmacology of mesolimbic
dopamine neurons: a dual-probe microdialysis study in the ventral tegmental area and
nucleus accumbens of the rat brain. The Journal of Neuroscience, 16(8), 2605–2611.
Witten, I. B., Steinberg, E. E., Lee, S. Y., Davidson, T. J., Zalocusky, K. A., Brodsky, M., …
Deisseroth, K. (2011). Recombinase-Driver Rat Lines: Tools, Techniques, and
Optogenetic Application to Dopamine-Mediated Reinforcement. Neuron, 72(5), 721–
733. http://doi.org/10.1016/j.neuron.2011.10.028
Witten, I. B., Steinberg, E. E., Lee, S. Y., Davidson, T. J., Zalocusky, K. A., Brodsky, M., …
others. (n.d.). Neuron, Volume 72 Supplemental Information Recombinase-Driver Rat
Lines: Tools, Techniques, and Optogenetic Application to Dopamine-Mediated
52

Reinforcement. Retrieved from
http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.368.774&rep=rep1&type=pdf
Yamaguchi, T., Sheen, W., & Morales, M. (2007). Glutamatergic neurons are present in the
rat ventral tegmental area: Glutamatergic neurons in the VTA. European Journal of
Neuroscience, 25(1), 106–118. http://doi.org/10.1111/j.1460-9568.2006.05263.x
You, Z.-B., Tzschentke, T. M., Brodin, E., & Wise, R. A. (1998). Electrical Stimulation of the
Prefrontal Cortex Increases Cholecystokinin, Glutamate, and Dopamine Release in the
Nucleus Accumbens: an In Vivo Microdialysis Study in Freely Moving Rats. The
Journal of Neuroscience, 18(16), 6492–6500.
Zhang, F., Gradinaru, V., Adamantidis, A. R., Durand, R., Airan, R. D., de Lecea, L., &
Deisseroth, K. (2010). Optogenetic interrogation of neural circuits: technology for
probing mammalian brain structures. Nature Protocols, 5(3), 439–456.
http://doi.org/10.1038/nprot.2009.226
Zhang, F., Wang, L.-P., Boyden, E. S., & Deisseroth, K. (2006). Channelrhodopsin-2 and
optical control of excitable cells. Nature Methods, 3(10), 785–792.
http://doi.org/10.1038/nmeth936
Zhao, S., Ting, J. T., Atallah, H. E., Qiu, L., Tan, J., Gloss, B., … Feng, G. (2011). Cell typespecific channelrhodopsin-2 transgenic mice for optogenetic dissection of neural circuitry
function. Nature Methods, 8(9), 745–752. http://doi.org/10.1038/nmeth.1668

53

Appendix A

54

Appendix B
Image 1

This image demonstrates the coordinates were in a dopamine rich ventral tegmental area.
The green color in the image is a florescent marker bound to tyrosine hydroxylase. The
blue color is named 4’,6-diamidino-2-phenylindole (DAPI), it is a florescent DNAbinding protein that stains cellular nuclei. This effectively illuminates where the DNA,
nucleus, and cell body of neurons exist. The large black path in the center is the tract left
by the injection needle.
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Image 2

This image shows the ventral tegmental area coordinates from a sterotaxic map (Paxinos,
1997).

56

Image 3

Image 3 shows the light testing equipment in action, each implant passed the minimum
requirement of 5 mWs of 465 nm light wavelength emittion.
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Image 4

Image 4 shows one of the subjects connected to the fibers in the locomotor enclosure.
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Image 5

Image 5 shows the video camera above the locomotor enclosure.
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Image 6

Image 6 shows the fibers in the locomotor enclosure.
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Image 7

Image 7 shows the end of a fiber lit up by 465 nm wavelengths of light.
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Image 8

Image 8 Full Sequence Map for pAAV-EF1a-double floxed-hChR2(H134R)-EYFPWPRE-HGHpA. This was a gift from Karl Deisseroth (Addgene plasmid # 20298). Map
generated by Addgene from full sequence supplied by Karl Deisseroth.
Image 9
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Image 9 shows individual data points during the final series of raclopride.
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